Catalysts for Alexion Pharmaceuticals Inc
18 tracked
Sep 26, 2025
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Jun 27, 2025
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Feb 28, 2025
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Sep 19, 2024
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Jun 28, 2024
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Mar 22, 2024
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Mar 22, 2024
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Feb 8, 2024
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Jul 22, 2022
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Apr 27, 2022
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Jan 7, 2022
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Nov 22, 2021
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Jun 7, 2021
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Apr 22, 2021
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Oct 9, 2020
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Apr 30, 2020
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Oct 18, 2019
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→
Dec 21, 2018
approval
ULTOMIRIS (RAVULIZUMAB-CWVZ) — FDA approval
Alexion Pharmaceuticals Inc
→